Suppr超能文献

普芦卡必利疗效与便秘类型的相关性。

The association between prucalopride efficacy and constipation type.

机构信息

Colorectal Surgical Unit, Northern General Hospital, Sheffield, UK,

出版信息

Tech Coloproctol. 2013 Oct;17(5):555-9. doi: 10.1007/s10151-013-1017-8. Epub 2013 May 24.

Abstract

BACKGROUND

Prucalopride is a selective serotonin receptor agonist with prokinetic activity, indicated for women with chronic constipation in whom laxatives have failed to provide adequate relief. Data suggests an improvement in about 50 % of such patients but whether the therapeutic effect is on patients with slow transit constipation (STC) and/or obstructed defaecation syndrome (ODS), or even those with constipation-predominant irritable bowel syndrome (IBS-C) is unknown. We therefore assessed whether there is any association between prucalopride efficacy and constipation type.

METHODS

All patients receiving prucalopride between June 2010 and April 2012 at our institution were identified, and data analysed following a 4-week "test" period. Patients were sub-grouped as those suffering with ODS, STC, mixed (ODS and STC) or IBS-C based on symptomatology and investigations. Subjective assessment of patient satisfaction and continuation of medication were taken as positive outcomes and analysed for each sub-type along with any side effects.

RESULTS

Sixty-nine patients met our criteria. Data were available for 59 women (median age 46 years, range 17-79 years). Sixty-five per cent of prescriptions came from colorectal surgeons. Overall, 25 out of 59 (42 %) patients improved, according to our criteria, after the 4-week trial period. Seventeen patients (29 %) had ODS, 26 (44 %) had STC, 7 (12 %) had mixed symptoms and 9 (15 %) had IBS-C. At 4 weeks, 10 out of 17 patients (59 %) with ODS had improved compared with 4 out of 9 patients (44 %) with IBS-C, 3 out of 7 patients (43 %) with mixed symptoms and 8 out of 26 (31 %) patients with STC. The underlying disorder did not predict whether or not a patient responded to the 4-week trial period (p = 0.32). Nine patients (15 %) experienced side effects that precluded further use.

CONCLUSIONS

Patients with all categories of constipation may respond to prucalopride. A trial regime may be indicated regardless of the aetiology of the constipation.

摘要

背景

普芦卡必利是一种选择性 5-羟色胺受体激动剂,具有促动力作用,用于治疗泻药治疗未能充分缓解的慢性便秘的女性患者。数据表明,约 50%的此类患者症状得到改善,但治疗效果是针对慢传输型便秘(STC)和/或出口梗阻型便秘综合征(ODS)患者,还是甚至针对便秘型肠易激综合征(IBS-C)患者尚不明确。因此,我们评估了普芦卡必利疗效与便秘类型之间是否存在关联。

方法

在我们机构,所有在 2010 年 6 月至 2012 年 4 月期间接受普芦卡必利治疗的患者均被识别出来,并在为期 4 周的“测试”期后进行数据分析。根据症状和检查结果,将患者分为 ODS、STC、混合(ODS 和 STC)或 IBS-C 亚组。将患者满意度的主观评估和药物的持续使用作为积极结果,并与每种亚组的任何副作用一起进行分析。

结果

69 名患者符合我们的标准。59 名女性的数据可用(中位年龄 46 岁,范围 17-79 岁)。65%的处方来自结直肠外科医生。总体而言,在为期 4 周的试验期后,根据我们的标准,59 名患者中有 25 名(42%)得到改善。17 名患者(29%)患有 ODS,26 名患者(44%)患有 STC,7 名患者(12%)患有混合症状,9 名患者(15%)患有 IBS-C。在 4 周时,17 名 ODS 患者中有 10 名(59%)改善,而 9 名 IBS-C 患者中有 4 名(44%),7 名混合症状患者中有 3 名(43%),26 名 STC 患者中有 8 名(31%)。潜在疾病并不能预测患者是否对 4 周试验期有反应(p=0.32)。9 名患者(15%)出现了副作用,无法继续使用该药。

结论

所有类型的便秘患者均可能对普芦卡必利有反应。无论便秘的病因如何,试验治疗方案可能都是指征。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验